The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial.
Omara DogarDeepa BaruaMelanie BoeckmannHelen ElseyRazia FatimaRhian GabeRumana HuqueAda KedingAmina KhanDaniel KotzEva KralikovaJames N NewellIveta NohavovaSteve ParrottAnne ReadshawLottie RenwickAziz SheikhKamran Siddiqinull nullPublished in: Addiction (Abingdon, England) (2018)
This is the first smoking cessation trial of cytisine in low- and middle-income countries evaluating both cessation and TB outcomes. If found effective, cytisine could become the most affordable cessation intervention to help TB patients who smoke.
Keyphrases
- smoking cessation
- randomized controlled trial
- mycobacterium tuberculosis
- replacement therapy
- end stage renal disease
- study protocol
- ejection fraction
- newly diagnosed
- placebo controlled
- chronic kidney disease
- phase iii
- phase ii
- systematic review
- peritoneal dialysis
- prognostic factors
- clinical trial
- emergency department
- type diabetes
- adipose tissue
- pulmonary tuberculosis
- radiation therapy
- insulin resistance
- hiv infected
- patient reported
- phase ii study
- glycemic control